EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation
This study suggests that therapeutically targeting EZH2 or HDAC1 activity may reverse the profound multiple myeloma–induced osteoblast suppression and allow repair of the lytic lesions. Mol Cancer Res; 15(4); 405–17. ©2017 AACR.
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Adamik, J., Jin, S., Sun, Q., Zhang, P., Weiss, K. R., Anderson, J. L., Silbermann, R., Roodman, G. D., Galson, D. L. Tags: Chromatin, Epigenetics, and RNA Regulation Source Type: research
More News: Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | Mergers and Aquisitions | Myeloma | Study